<?xml version="1.0" encoding="UTF-8"?>
<p>Just three new compounds, bedaquiline, delamanid, and pretomanid, have received approval for use against TB [
 <xref rid="B2" ref-type="bibr">2</xref>, 
 <xref rid="B3" ref-type="bibr">3</xref>]. Although they appear to have good anti-TB activity and could be useful for treating strains resistant to other agents, their potential for side effects and the possible emergence of resistant strains [
 <xref rid="B4" ref-type="bibr">4</xref>, 
 <xref rid="B5" ref-type="bibr">5</xref>] have led to caution and reservations about their appropriate role in treatment regimens. Therefore, the search for new drugs that are safe and effective in the control of TB continues to be a priority.
</p>
